Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

Diepolder, Helmut M.; Zachoval, Reinhart; Hoffmann, Robert M.; Jung, M; Pape, Gerd R.; Wierenga, Eddy A.; Santantonio, T.; Eichenlaub, D.

doi:10.1016/s0140-6736(95)91691-1

Cited by 669 publications

(521 citation statements)

References 9 publications

Supporting

Mentioning

482

Contrasting

Unclassified

Order By: Relevance

“…However, they are weak and inefficient [3][4][5][6][7][8][9][10]14,15,45]. In fact, the frequency of CTL precursors against HCV proteins found in patients with chronic hepatitis C is very low, in comparison to that found in HIV or CMV infections [46][47][48].…”

Section: Discussionmentioning

confidence: 99%

“…It is characterised by a high tendency to chronicity, which often progresses to cirrhosis and liver cancer [2]. Viral clearance after acute hepatitis or after IFN-␣ therapy is usually associated with strong CD4 and CD8 T cell responses [3][4][5][6][7][8][9][10][11][12]. In particular, cellular T helper immune response against nonstructural NS3 HCV protein has been associated with viral clearance after acute infection, whereas absence of this Tcell response leads to viral persistence and chronic hepatitis [9,13].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Arribillaga

Sarobe

Arina

et al. 2005

Vaccine

View full text Add to dashboard Cite

The induction of protective or therapeutic cellular immunity against hepatitis C virus (HCV) is a difficult goal. In a previous work we showed that immunization with a recombinant adenovirus encoding HCV-NS3 (RAdNS3) could partially protect mice from challenge with a vaccinia virus encoding HCV antigens. We sought to investigate whether systemic administration of an immunostimulatory monoclonal antibody directed against the lymphocyte surface molecule CD137 could enhance the immunity elicited by RAdNS3. It was found that treatment with anti-CD137 mAb after the administration of a suboptimal dose of RAdNS3 enhanced cytotoxic and T helper cell responses against HCV NS3. Importantly, the ability of RAdNS3 to induce protective immunity against challenge with a recombinant vaccinia virus expressing HCV proteins was markedly augmented. Thus, combination of immunostimulatory anti-CD137 mAb with recombinant adenoviruses expressing HCV proteins might be useful in strategies of immunization against HCV.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Arribillaga

Sarobe

Arina

et al. 2005

Vaccine

View full text Add to dashboard Cite

show abstract

“…• Clearance of acute infection in both man and in chimpanzee models is accompanied by strong CD4 + and CD8 + T cell responses against numerous HCV derived antigens [11,[13][14][15][16].…”

Section: Cellular Immunology Of Hcvmentioning

confidence: 99%

“…The evidence was obtained first for CD4 + T cell responses and initially some specific epitopes were highlighted as potentially 'protective' [13]. Although these do appear to be targeted, this is not exclusive and responses to other gene products are also seen [17].…”

Section: Cellular Immunology Of Hcvmentioning

confidence: 99%

Cellular immune responses against hepatitis C virus: the evidence base 2002

Ward¹,

Lauer

Isba³

et al. 2002

Clinical and Experimental Immunology

137

102

View full text Add to dashboard Cite

SUMMARYHepatitis C virus (HCV) is an RNA virus which is estimated to persistently infect about 170 million people worldwide. After acute infection, there is an initial period during which long-term outcome is decided. There is strong evidence that the cellular immune responses, involving both CD4 + and CD8 + T lymphocytes, are involved at this stage and it is their effectiveness which determines outcome. What is not understood is what determines their effectiveness. The most important component of this is likely to be some aspect of epitope selection, itself dictated by host MHC. Thus, to understand host immunity to HCV, we need to have a detailed understanding of the peptides involved in T lymphocyte responses. In this review, we discuss the peptide epitopes that have been identified so far, and their potential significance. We relate this to a scheme of host defence which may be useful for understanding natural and vaccine-induced immunity.

show abstract

“…A predominance of TH1/0 lymphokines has also been shown in peripheral NS3-specific T-cell clones derived from patients with acute self-limited hepatitis C infection. 29 Acute and chronic hepatitis C infection is associated with a TH1/0 lymphokine profile. The recurrent HCV infection in the transplant setting is no exception to this rule despite the immunosuppressive regimen.…”

Section: Discussionmentioning

confidence: 99%

Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection

Schirren¹,

Jung²,

Worzfeld

et al. 2000

Liver Transpl

Self Cite

View full text Add to dashboard Cite

Possible mechanism involving T-lymphocyte response to non-structural protein 3 in viral clearance in acute hepatitis C virus infection

Cited by 669 publications

References 9 publications

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Enhancement of CD4 and CD8 immunity by anti-CD137 (4-1BB) monoclonal antibodies during hepatitis C vaccination with recombinant adenovirus

Cellular immune responses against hepatitis C virus: the evidence base 2002

Cytokine profile of liver- and blood-derived nonspecific T cells after liver transplantation: T helper cells type 1/0 lymphokines dominate in recurrent hepatitis C virus infection and rejection

Contact Info

Product

Resources

About